Abstract：Objective :To review current researches on clinical pharmacokinetics and pharmacodynamics of glucocorticoid prednisone/prednisolone in patients receiving renal transplantation in recent years, and to provide references for optimization of immune suppression treatment in the future. Methods :By searching the related literatures worldwide, the current status of related pharmacokinetic/ pharmacodynamic researches on prednisone/prednisolone in patients receiving renal transplantation was summarized as well as its future developing direction. Results : Glucocorticoids have been used for many years but their clinical dosing regimens usually depend on physician's experience lacking guidance of pharmacokinetic/pharmacodynamic studies. Thus there are multiple side effects in patients receiving bolus or long-term treatment. At present, clinical pharmacokinetic and pharmacodynamic studies of prednisone/prednisolone in patients receiving renal transplantation have some limitations: the calculation of pharmacokinetic parameters used non-compartmental analysis and two-step statistical methods; in most researches, blood concentrations of total drug concentration are determined rather than free drug concentrations. Pharmacodynamic studies are mostly limited to correlation between drug exposure and toxicity. conclusion : There have been a few studies on clinical pharmacokinetics and pharmacodynamics of prednisone/prednisolone in patients receiving renal transplantation which are still not comprehensive. Quantitative relationships need to be surveyed to develop guidance of individualized dosage strategies in the future.
[1] 黄绍宽. 糖皮质激素在肾移植中的应用[J]. 国外医学移植与血液净化分册, 2004, 2(3): 41-43.
[2] 史燕军. 非糖皮质激素免疫抑制方案在肾移植中的研究进展[J].国际泌尿系统杂志, 2006, 26(1):76-79.
[3] Bergmann T K, Barraclough K A, Lee K J, et al. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation[J]. Clin Pharmacokinet,2012, 51(11):711-741.
[4] Czock D, Keller F, Maximilian F, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids[J]. Clin Pharmacokinet 2005, 44 (1): 61-98.
[5] Jeng S, Chanchairujira T, Jusko W, et al. Prednisone metabolism in recipients of kidney or liver transplants and in lung recipients receiving ketoconazole[J]. Transplantation, 2003, 75(6):792-795.
[6] Coutinho A E, Chapman K E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights[J]. Molecular Cellular Endocrinol, 2011,335(1): 2-13.
[7] 孙特. 糖皮质激素、来氟米特、霉酚酸酯对T 淋巴细胞亚群及细胞因子的影响[J]. 武警医学, 2009, 20(12): 1129-1132.
[8] Wieland E, Olbricht C J, Süsal C, et al. Biomarkers as a tool for management of immunosuppression in transplant patients[J]. Ther Drug Monit, 2010, 32(5): 560-572.
[9] 李鑫, 杨蕊, 臧强，等. 糖皮质激素的药理作用机制研究进展[J].国际药学研究杂志, 2009, 36(1): 27-30.
[10] Atalar K, Afzali B, Lord G, et al. Relative roles of Th1 and Th17 effector cells in allograft rejection[J]. Curr Opin Organ Transplant,2009, 14(1):23-29.
[11] Millán O, Rafael-Valdivia L, Torrademé E, et al. Intracellular IFN-c and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients[J]. Cytokine, 2013, 61（2）: 556-564.
[12] Gras J, Wieers G, Vaerman J L, et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients[J]. Liver Transpl, 2007, 13（3）: 426-433.
[13] Newton R. Molecular mechanisms of glucocorticoid action: what is important? [J].Thorax, 2000, 55(7):603-613.
[14] Knight S R, Morris P J. Steroid avoidance or withdrawal following renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis[J]. Transplantation,2010, 89 (1): 1-14.
[15] Ramakrishnan R, DuBois D C, Almon R R, et al. Fifth-generation model for corticosteroid pharmacodynamics: application to steadystate receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats[J]. J Pharmacokinet Pharmacodyn, 2002, 29(1):1-24.
[16] Hazra A, Pyszczynski N, DuBois D C, et al. Modeling receptor/ gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids[J]. J Pharmacokinet Pharmacodyn,2007, 34（5）:643-667.
[17] Hazra A, Pyszczynski N, DuBois D C, et al. Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats[J]. Pharm Res, 2008, 25(4):769-780.
[18] Earp J C, DuBois D C, Molano D S, et al. Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in lewis rats[J]. J Pharmacol Experimental Therapeutics, 2008, 326(2):532-545.
[19] Earp J C, DuBois D C, Molano D S, et al. Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in lewis rats with collagen-induced arthritis[J]. J Pharmacol Experimental Therapeutics, 2008, 326(2):546-554.
[20] Decker S O, Keller F, Mayer J, et al. Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants[J]. Med Klin (Munich), 2009,104(6):429-433.
2015, Vol. 13 
